Immunological effectiveness of hepatitis B vaccination in deviation from vaccination schedule in healthy children and children with chronic diseases

Introduction. Vaccination is the primary method of preventing hepatitis B (HBV). Immunization performed according to the standard schedule often provides protective level of antibodies against HBV. However, the frequency deviation of the immunization schedule in children due to unjustified medical contraindication is the current problem in Russia. At the same time, there is currently no clear strategy for patients with significant deviations of the vaccination schedule, especially regarding extending the interval between the first and third administration of the HBV vaccine. The aim is to evaluate the immunological effects of vaccination against hepatitis B in the vaccination schedule deviation in healthy children and children with chronic diseases.

Materials and methods. Eighty-one 0.7–11.7 year child with a disrupted schedule of vaccination against HBV was observed. The children were divided into two groups: children vaccinated within 12–35 months (group 1, n = 48) and children immunized more than 36 months after the first vaccination (group 2, n = 33). Children with chronic forms of pathology were included in both study groups. Blood tests for HBV antibodies after vaccination were performed 1–3 months after the third vaccination.

Results. The average concentration of antibodies in the range of 10–1000 mMEd/ml in children of group 1 was significantly higher than in children of group 2 (p = 0.037). In addition, children with chronic diseases were significantly more likely to have an anti-HBs titer higher than 1000 mMEd/ml after the third vaccination than healthy children (p = 0.012).

Conclusion. An increase in the interval between the first and third administration of the hepatitis B vaccine leads to a rise in the number of children who are not immune to hepatitis B. Chronic diseases fail to affect the immune response due to the introduction of the hepatitis B vaccine, even if the immunization schedule is disrupted.

Contribution:
Tkachenko N.E., Yasakov D.S. — the concept and design of the study;
Yasakov D.S., Vershinina M.G., Alyabieva N.M. — collecting and processing material;
Yasakov D.S., Makarova S.G. — writing text;
Fisenko A.P., Makarova S.G. — text editing.
All authors — approval of the final version of the article.

Acknowledgement. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: June 11, 2021
Accepted: June 23, 2021
Published: July 16, 2021

1. Ozeretskovskiy N.A., Shalunova N.V., Petruchuk E.M., Indikova I.N. Vaccinoprophylaxis of hepatitis B. Epidemiologiya i vaktsinoprofilaktika. 2015; 14(2): 87–95. (in Russian)

2. Wilkins T., Sams R., Carpenter M. Hepatitis B: screening, prevention, diagnosis, and treatment. Am. Fam. Physician. 2019; 99(5): 314–23.

3. Kwon S.Y., Lee C.H. Epidemiology and prevention of hepatitis B virus infection. Korean J. Hepatol. 2011; 17(2): 87–95. https://doi.org/10.3350/kjhep.2011.17.2.87

4. Zimmermann P., Curtis N. Factors that influence the immune response to vaccination. Clin. Microbiol. Rev. 2019; 32(2): e00084-18. https://doi.org/10.1128/CMR.00084-18

5. Duval B., Deceuninck G. Seroprotection rates after late doses of hepatitis B vaccine. Pediatrics. 2002; 109(2): 350–1. https://doi.org/10.1542/peds.109.2.350

6. Halsey N.A., Moulton L.H., O’Donovan J.C., Walcher J.R., Thoms M.L., Margolis H.S., et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics. 1999; 103(6 Pt. 1): 1243–7. https://doi.org/10.1542/peds.103.6.1243

7. Zampino R., Boemio A., Sagnelli C., Alessio L., Adinolfi L.E., Sagnelli E., et al. Hepatitis B virus burden in developing countries. World J. Gastroenterol. 2015; 21(42): 11941–53. https://doi.org/10.3748/wjg.v21.i42.11941

8. Tkachenko N.E., Yasakov D.S., Fisenko A.P., Makarova S.G. Current problems of vaccination against hepatitis B. Rossiyskiy pediatricheskiy zhurnal. 2020; 23(5): 313–7. https://doi.org/10.18821/1560-9561-2020-23-5-313-317 (in Russian)

9. Buchkova T.N., Zryachkin N.I., Polyakov K.A., Chebotareva G.I. Reasons for delayed immunization against hepatitis B. Detskie infektsii. 2012; 11(3): 36–8. (in Russian)

10. Zuckerman J.N. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J. Med. Virol. 2006; 78(2): 169–77. https://doi.org/10.1002/jmv.20524

11. Jafarzadeh A., Zarei S., Shokri F. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates. Vaccine. 2008; 26(2): 269–76. https://doi.org/10.1016/j.vaccine.2007.10.044

12. Ponde R.A.A. Expression and detection of anti-HBs antibodies after hepatitis B virus infection or vaccination in the context of protective immunity. Arch. Virol. 2019; 164(11): 2645–58. https://doi.org/10.1007/s00705-019-04369-9

13. Kamath G.R., Shah D.P., Hwang L.Y. Immune response to hepatitis B vaccination in drug using populations: a systematic review and meta-regression analysis. Vaccine. 2014; 32(20): 2265–74. https://doi.org/10.1016/j.vaccine.2014.02.072

14. WHO Publication. Hepatitis B vaccines: WHO position paper – recommendations. Vaccine. 2010; 28(3): 589–90. https://doi.org/10.1016/j.vaccine.2009.10.110

15. Fanning G.C., Zoulim F., Hou J., Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat. Rev. Drug. Discov. 2019; 18(11): 827–44. https://doi.org/10.1038/s41573-019-0037-0

16. Gomes C., Wong R.J., Gish R.G. Global perspective on hepatitis B virus infections in the era of effective vaccines. Clin. Liver Dis. 2019; 23(3): 383–99. https://doi.org/10.1016/j.cld.2019.04.001

17. Van Loveren H., Van Amsterdam J.G., Vandebriel R.J., Kimman T.G., Rümke H.C., Steerenberg P.S., et al. Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors. Environ. Health Perspect. 2001; 109(8): 757–64. https://doi.org/10.1289/ehp.01109757

18. Zheng Z., Diaz-Arévalo D., Guan H., Zeng M. Noninvasive vaccination against infectious diseases. Hum. Vaccin. Immunother. 2018; 14(7): 1717–33. https://doi.org/10.1080/21645515.2018.1461296